InMed Pharmaceuticals Inc

InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. The firm's pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer's disease, dry Age-Related Macular Degeneration, or dry AMD, and Epidermolysis Bullosa, or EB. Its INM-901 is a small molecule, disease-modifying drug developed for treatment for Alzheimer's disease. The company also offers various modes of administration, including oral delivery. Its INM-089 is a drug candidate for dry age-related macular degeneration. Its INM-755 is a cannabinol cream topical product candidate intended as a therapy in dermatological diseases.